Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Condition: CPVT1 · Heart Defects, Congenital · Heart Diseases · Sponsor: Cardurion Pharmaceuticals, Inc.
About this study
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (11)
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | — |
| Cleveland Clinic Children's Hospital | Cleveland, Ohio, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
| Stollery Children's Hospital University of Alberta | Edmonton, Alberta, Canada | — |
| University of British Columbia (UBC) Hospital | Vancouver, British Columbia, Canada | — |
| British Columbia Children's Hospital | Vancouver, British Columbia, Canada | — |
| University of Western Ontario | London, Ontario, Canada | — |
| Hôptal Nord Laennec | Nantes, Loire-Atlantique, France | — |
| Hôpital Louis Pradel | Bron, France | — |
| Groupe Hospitalier Bichat Claude Bernard | Paris, France | — |
| IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit | Pavia, Lombardy, Italy | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06005428